Skip to main content
Zura Bio Ltd logo

Zura Bio Ltd — Investor Relations & Filings

Ticker · ZURA ISIN · KYG507521071 LEI · 549300LQXD6M2MIQFN24 US Manufacturing
Open in API
Filings indexed 394 across all filing types
Latest filing 2024-08-08 Capital/Financing Update
Country KY Cayman Islands
Listing US ZURA

About Zura Bio Ltd

https://zurabio.com/

Zura Bio Ltd. is a multi-asset, clinical-stage biotechnology company focused on developing novel medicines for severe autoimmune and inflammatory disorders. The company's strategy centers on dual-pathway biology, aiming to create transformative solutions for patients whose needs are not adequately met by single-pathway medicines. Its development portfolio includes the therapeutic candidates tibulizumab (ZB-106), crebankitug (ZB-168), and torudokimab (ZB-880). Zura Bio's mission is to enhance patient well-being by developing innovative dual-pathway antibody therapies that demonstrate efficacy, safety, and dosing convenience for challenging immunological conditions.

Recent filings

Filing Released Lang Actions
424B3
Capital/Financing Update Classification · 95% confidence The document is a detailed prospectus/offer to exchange filed pursuant to Rule 424(b)(3) related to a warrant exchange offer and consent solicitation by Zura Bio Limited. It includes terms of the offer, consent solicitation details, registration statement references (Form S-4), and legal and procedural information. The document is not a financial report, earnings release, or management discussion but rather a capital markets transaction document focused on exchanging warrants for shares and amending warrant agreements. This fits the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes. The document length (15,000 characters) and content confirm it is the actual offer document, not just an announcement or regulatory filing. Therefore, the correct classification is CAP with high confidence.
2024-08-08 English
Director's Dealing 2024
Director's Dealing
2024-08-08 English
Regulatory Filings 2024
Regulatory Filings Classification · 95% confidence The document is a letter from Zura Bio Limited to the SEC requesting acceleration of the effective date for a Registration Statement on Form S-4. This is a regulatory communication related to a filing process, specifically concerning the timing of a registration statement becoming effective. It does not contain financial data, audit information, or detailed report content. The document is short (963 characters) and is a formal request rather than a report or announcement of results. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2024-08-06 English
Merger & Acquisition 2024
Merger & Acquisition Classification · 100% confidence The document is a detailed response letter from legal counsel to the SEC's Division of Corporation Finance, Office of Mergers & Acquisitions, regarding comments on a Schedule TO-I filing and an amended Registration Statement on Form S-4. The Schedule TO relates to a tender offer, and the letter addresses SEC staff comments on disclosures, conditions, and legal compliance related to the tender offer and consent solicitation. The document references specific SEC rules and regulations, amendments to filings, and detailed legal and financial disclosures. This type of document is typical of filings related to merger and acquisition activities, specifically tender offers and exchange offers. It is not a financial report, earnings release, or general regulatory filing but is directly related to M&A activity and tender offer compliance. Therefore, the appropriate classification is Merger & Acquisition (MA). The document length and detail confirm it is not a brief announcement or certification but a substantive filing related to M&A.
2024-07-25 English
S-4/A
Capital/Financing Update Classification · 95% confidence The document is an Amendment No. 1 to Form S-4 Registration Statement filed with the SEC. It is a registration statement under the Securities Act of 1933 related to an offer to exchange warrants for shares and a consent solicitation to amend the warrant agreement. The document includes detailed terms of the offer, consent solicitation, and related legal and procedural information. Form S-4 is a registration statement used for securities issued in connection with mergers, acquisitions, or exchange offers. This filing is not a financial report, earnings release, or management discussion, but a regulatory filing related to a capital transaction. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2024-07-25 English
FORM 8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content specifically details a management change: the CEO transition and related settlement agreement. It includes information about the departure of a director/officer and compensatory arrangements. There are no financial statements or quarterly/yearly financial results presented, so it is not an Annual Report (10-K) or Interim Report (IR). It is not a proxy statement or voting results announcement. The key focus is on management changes and related agreements, which fits the Board/Management Information category (MANG). The document length is about 5,091 characters, which is consistent with a detailed 8-K filing on management changes. Therefore, the correct classification is MANG with high confidence.
2024-07-25 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.